Atezolizumab (Tecentriq)

OFFICE ADMINISTRATION

FDA Approved Indications:
  • Treatment of locally advanced or metastatic urothelial carcinoma in patients who:
    • have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy, OR
    • are not eligible for cisplantin-containing chemotherapy
  • Treatment of metastatic non-small cell lung cancer in patients who have disease progression during or following platinum-containing chemotherapy.  Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Tecentriq
Patients must meet the following criteria for the indications above:
  • Prescribed by an oncologist, AND
  • Patient is at least 18 years of age, AND
  • Chart note documentation confirms above diagnosis, AND
  • For advance or metastic urothelial carcinoma: the patient has disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy, OR is not eligible for cisplatin-containing chemotherapy
  • For metastic non-small cell lung cancer: the patient has disease progression during or following platinum-containing chemotherapy, AND patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to starting Tecentriq
Dosing:
  • Administer 1200 mg as an IV infusion over 60 minutes every 3 weeks
Approval:
  • One year